Intersection · Evidence × randomised trial
Evidence topics tagged randomised trial
Topics in Evidence carrying the tag randomised trial. Randomised controlled trial evidence.
66 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: indirect comparison between two programmes, defended and attacked
Journal club: indirect comparison between two programmes, defended and attacked Writing it up because I had to work it out twice and would rather nobody else did. Trying to work out what would count as…
|
+122 | 131 | 5.2k | just now |
|
Journal club: STEP 1 and the treatment-policy estimand
Journal club: STEP 1 and the treatment-policy estimand Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
|
3 | 11k | 9h | |
|
What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. Statistical analysis plan, and specifically the version…
|
2 | 6.6k | 10h | |
|
Second pass at: Reading a trial's population section before its results
Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. Reading STEP 1 ( N Engl J Med , 2021) for the…
|
4 | 9.5k | 10h | |
|
Primary endpoint hierarchies and why order matters — one year on
On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…
|
+56 | 61 | 37k | 11h |
|
Composite endpoints and the component doing the work
Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about composite endpoints in one place, because…
|
+3 | 7 | 33k | 13h |
|
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Posting a small dataset on STEP 8. It is…
|
+18 | 22 | 656 | 13h |
|
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Working notes on semaglutide in MASH rather than a conclusion.…
|
+24 | 28 | 17k | 15h |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…
|
+70 | 76 | 4.8k | 15h |
|
Journal club: the CagriSema phase 2 combination paper
On the subject in the title: Journal club: the CagriSema phase 2 combination paper Working notes rather than a conclusion. CagriSema phase 2 combination paper — I have the observation and I do not trust my…
|
2 | 329 | 21h | |
|
Journal club: what we got wrong in an earlier session
On the subject in the title: Journal club: what we got wrong in an earlier session Working notes rather than a conclusion. Bringing a claim rather than a paper, because the claim is the thing circulating. The…
|
+114 | 125 | 2.5k | 23h |
|
Subgroup analyses: pre-specified versus discovered
Subgroup analyses: pre-specified versus discovered — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on subgroup analyses, and I…
|
2 | 27k | 1d | |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. Reading SUSTAIN 6 ( N Engl J Med , 2016) for the population rather than the effect,…
|
+110 | 122 | 46k | 1d |
|
Journal club: orforglipron phase 2 and the non-peptide question
Journal club: orforglipron phase 2 and the non-peptide question Writing it up because I had to work it out twice and would rather nobody else did. Orforglipron phase 2, and specifically the version of it that…
|
+120 | 132 | 13k | 1d |
|
[2026 update] Journal club: FLOW and the renal composite, component by component
Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what…
|
2 | 21k | 9d | |
|
Interim analyses and stopping rules
Interim analyses and stopping rules Writing it up because I had to work it out twice and would rather nobody else did. Asking about interim analyses and stopping rules on behalf of the question I keep seeing…
|
+25 | 29 | 35k | 16d |
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
|
+6 | 10 | 13k | 28d |
|
Run-in periods and the population they select
On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. An honest uncertainty about run-in periods rather than a disguised assertion. I do not know…
|
+130 | 142 | 7.3k | 1mo |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Posting a small dataset on SELECT. It is mine, it is…
|
4 | 1.3k | 1mo | |
|
Reading a trial's population section before its results
On the subject in the title: Reading a trial's population section before its results Working notes rather than a conclusion. Reading STEP 2 ( Lancet , 2021) for the population rather than the effect, which I…
|
+91 | 109 | 22k | 2mo |
|
Subgroup analyses: pre-specified versus discovered — a second dataset
On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…
|
+71 | 79 | 906 | 3mo |
|
Primary endpoint hierarchies and why order matters
Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about primary endpoint hierarchies in a thread last spring and…
|
4 | 308 | 3mo | |
|
Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Bringing a claim rather than a paper, because the claim…
|
+116 | 120 | 23k | 3mo |
|
Follow-up: What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not I have a specific reason for asking rather than idle curiosity, and the context is below. A follow-up question about statistical analysis plan…
|
2 | 7.2k | 3mo | |
|
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…
|
4 | 22k | 3mo | |
|
Run-in periods and the population they select — the long version
Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Run-in periods, deliberately narrow,…
|
2 | 8.9k | 4mo | |
|
Journal club: PIONEER 6 as a safety trial
Posting this under the heading it deserves: Journal club: PIONEER 6 as a safety trial Everything below is what sits behind that. Reading PIONEER 6 ( N Engl J Med , 2019) for the population rather than the…
|
+14 | 18 | 262 | 5mo |
|
Non-inferiority margins: how they are chosen and how they are abused — a second dataset
Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Non-inferiority…
|
+32 | 37 | 574 | 5mo |
|
[2026 update] Reading a supplementary appendix and finding the interesting part
On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Collecting what is known about Reading a supplementary appendix in one…
|
+39 | 44 | 8.2k | 5mo |
Sponsored
Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing →
Sponsored
GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →